POPULARITY
25 episodes with leora horn
24 episodes with leora horn
5 episodes with leora horn
4 episodes with leora horn
2 episodes with leora horn
2 episodes with leora horn
Dr. Leora Horn, having recently moved from academic medicine to AstraZeneca, talks with hosts Charu Aggarwal & Jack West about the decision to change roles, her efforts to balance work & family, & how to cultivate opportunities for junior faculty.
On today's episode, meet Dr. Leora Horn. Dr. Horn is the Global Clinical Head for Lung Cancer and Lung Cancer Strategy at AstraZeneca. She leads the company's global research and development in lung cancer. In her role, she partners with lung cancer teams from across AstraZeneca Oncology to rapidly progress their research and deliver on their commitment to cure more patients with the disease. Before coming to AstraZeneca, Dr. Horn was the Ingram Associate Professor of Cancer Research and Director of the Clinical Research Section of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center.
Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: First-line treatment for patients with metastatic NSCLC without a targetable tumor mutation — Dr Horn. CME information and select publications
In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expressionChoosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expressionLeveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumabSTK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapyTreatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitorRechallenging after stopping immune checkpoint inhibitor due to immune-related adverse eventsPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs
In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:How to approach discordant results with liquid vs tissue biopsiesRepeating NGS testing at progressionSelecting urgent treatment when molecular results are not yet availablePoint mutations in NTRK fusion–positive diseaseSelecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKISelecting first-line and second-line therapy for ROS1-positive diseaseStandard of care for MET-altered diseaseSelecting second-line therapy for RET fusion–positive disease after first-line TKIPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs
Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 1: A roundtable discussion featuring Drs John Heymach, Leora Horn, Melissa Johnson and Benjamin Levy. Biomarker assessment for patients with metastatic non-small cell lung cancer (NSCLC) (00:00) Selection of first-line treatment for patients with metastatic NSCLC without actionable tumor mutations; role of immune checkpoint inhibitors (6:48) Case (Maria Picton, MD): A man in his mid-80s and previous smoker with metastatic adenocarcinoma of the lung and pleural effusion receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pembrolizumab (17:44) Case (G Richard Polkinghorn, MD): A man in his early 50s with metastatic squamous cell carcinoma of the lung receives ramucirumab and docetaxel as second-line therapy (23:16) Use of immune checkpoint inhibitors for patients with a history of autoimmune disease (37:40) Case (Dr Polkinghorn): A woman in her early 60s and current smoker with multiple sclerosis and COPD receives nivolumab for metastatic NSCLC and attains a complete remission (44:35) Treatment of metastatic NSCLC with actionable tumor mutations, including ALK rearrangements (48:51) Case (Joseph T Martins, MD): A woman in her mid-70s and previous smoker with metastatic NSCLC and a MET mutation (59:18) Case (Margaret A Deutsch, MD): A man in his mid-60s, a never smoker, with metastatic adenocarcinoma of the lung and a KIF5B-RET fusion receives cabozantinib (1:02:22) Activity and tolerability of the selective RET inhibitors pralsetinib and selpercatinib; preliminary results from the Phase III ADAURA trial evaluating adjuvant osimertinib (1:06:13) Management of metastatic NSCLC in the era of COVID-19; preliminary results from the TERAVOLT registry on the impact of COVID-19 on the care of patients with lung cancer (1:11:55) CME information and select publications
A roundtable discussion featuring clinical investigators Hossein Borghaei, DO, MS, Julie R Brahmer, MD, MSc, Edward B Garon, MD, MS, Ramaswamy Govindan, MD, John V Heymach, MD, PhD, Leora Horn, MD, MSc, Melissa L Johnson, MD and Benjamin Levy, MD, and general medical oncologists Margaret A Deutsch, MD, Joseph T Martins, MD, Maria Picton, MD and G Richard Polkinghorn, MD moderated by Neil Love, MD. Produced by Research To Practice.
The newest episode of Lung Cancer Considered, the IASLC's official podcast program, focuses on a discussion between lung cancer experts from the U.S. and Europe discussing COVID-19 with regard to lung cancer patients with experiences, results and actions from different parts of the world. This episode features a conversation between Dr. Marty Edelman, chair of department of hematology/oncology and a professor, department of hematology/oncology at Fox Chase Cancer Center; Dr. Leora Horn, Ingram associate professor of cancer research at Vanderbilt Ingram Cancer Center and clinical director, thoracic oncology program; and Dr. Solange Peters, professor and chair of thoracic oncology at the University of Hospital Lausanne (CHUV), and current president of ESMO.
Dr Leora Horn of Vanderbilt University Medical Center discusses outcomes for patients with lung cancer and COVID-19 as well as the human implications of social distancing. Additional Resources * AACR Virtual Annual Meeting I: April 27-28, 2020. (https://aacr20.onlineeventpro.freeman.com/) * COVID-19 and Cancer. AACR 2020. Session (https://aacr20.onlineeventpro.freeman.com/live-stream/15335630/COVID-19-and-Cancer) * Garassino, MC. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. AACR 2020. Abstract (https://www.abstractsonline.com/pp8/#!/9045/presentation/10927) * Minello A. The pandemic and the female academic. Nature 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32303729)
Marina Garassino and Leora Horn discuss their AACR study of COVID-19 in lung cancer.
Proceedings from the Second Annual Miami General Medical Oncology Symposium — Part 11: Lung Cancer. Featuring perspectives from Drs Hossein Borghaei, Leora Horn, Stephen V Liu and Gregory J Riely. Immune Checkpoint Inhibitors in Lung Cancer Immune Checkpoint Inhibitors in Locally Advanced and Small Cell Lung Cancer — Dr Liu Factors Affecting the Selection of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC); Role of PD-L1 in Current Decision-Making — Dr Borghaei Targeted Treatment of Lung Cancer First-Line Treatment for Patients with Metastatic EGFR-Mutated NSCLC and CNS Metastases — Dr Riely Treatment of BRAF-, NTRK- and RET-Positive NSCLC — Dr Horn CME information and select publications
This episode features Dr. Marty Edelman, Chair of the Department of Hematology/Oncology and a Professor, Department of Hematology/Oncology at Fox Chase Cancer Center. He is joined by Dr. Roy Herbst, a Professor of Medicine and Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center/ Yale School of Medicine; and Dr. Leora Horn, the Ingram Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Clinical Director, Thoracic Oncology Program. Together they discuss highlights from the 20th IASLC 2020 Lung Cancer Targeted Therapies conference in Santa Monica
Proceedings from a CME symposium held during the IASLC 2019 North America Conference on Lung Cancer. Featuring perspectives from moderator Dr Joel W Neal and faculty members Drs Nasser H Hanna, Leora Horn and Lecia V Sequist: Introduction (00:00) Evolving Therapeutic Algorithms in Small Cell Lung Cancer (SCLC) (1:04) Optimal Therapeutic Approaches for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations (21:55) Management of NSCLC with ALK Rearrangements (35:24) Current and Future Role of Existing and Emerging ROS1 Inhibitors (45:16) Treatment of Metastatic NSCLC with Other Targetable Tumor Mutations (56:06) Role of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Therapies for Metastatic NSCLC (1:15:41) CME information and select publications
Visiting Professors: Lung Cancer Edition — Part 2: Our discussion with Drs Horn and Ma highlights the following topics as well as cases from Dr Ma’s practice: Case: A woman in her mid-70s with Stage IV lung adenocarcinoma and a PD-L1 TPS of 70% experiences a pathologic fracture of the right femur while receiving first-line pembrolizumab (00:00) Pembrolizumab monotherapy versus carboplatin/pemetrexed/pembrolizumab as first-line therapy for patients with metastatic NSCLC and a high TPS (02:30) Radiation necrosis as a potential cause of pathologic fractures (05:18) Thyroid dysfunction and pancreatitis associated with pembrolizumab (08:12) Case: A man in his early 50s with metastatic lung cancer of ambiguous histology experiences a dramatic response to first-line nab paclitaxel/carboplatin (11:11) Utility of liquid biopsies in therapeutic decision-making for patients with metastatic lung cancer (13:03) Therapy for patients with metastatic lung cancer and CNS metastases (15:11) Therapeutic approach for patients with metastatic lung cancer of undetermined histology (20:30) Second-line therapy for patients with metastatic lung cancer (22:41) Case: A woman in her mid-80s with metastatic lung adenocarcinoma and a PD-L1 TPS of 30% receives pemetrexed/pembrolizumab and experiences dyspnea (28:14) Perspective on the approach to metastatic lung adenocarcinoma in elderly patients (30:52) Efficacy of ramucirumab as second-line therapy for patients with metastatic NSCLC (36:24) REVEL: Results of a Phase III trial evaluating the addition of ramucirumab to docetaxel after disease progression on platinum-based therapy for patients with Stage IV NSCLC (37:44) Comparison of the activity and tolerability of ramucirumab to that of bevacizumab in patients with metastatic squamous cell carcinoma of the lung (40:11) Ongoing clinical investigation of novel combination approaches with immune checkpoint inhibitors and anti-angiogenic agents (41:49) Case: A man in his mid-70s, a former smoker, with Stage III NSCLC initially treated with adjuvant chemoradiation therapy develops metastatic disease and is found to have a RET tumor mutation (43:40) Effects of tumor mutation burden and PD-L1 expression on response to immune checkpoint inhibitors (47:32) Perspective on the use of targeted therapy as first-line treatment for patients with metastatic NSCLC (49:32) Sequencing targeted therapy and immune checkpoint inhibitors for patients with metastatic NSCLC and actionable tumor mutations (51:08) Case: A woman in her early 60s with lung adenocarcinoma and oligometastatic disease in the brain receives first-line chemoradiation therapy (56:39) Cardiomyopathy associated with checkpoint inhibitor therapy (1:00:08) Prolonged responses to anti-PD-1/PD-L1 antibodies after cessation of therapy (1:03:27) PD-L1 expression as a predictor of response to immune checkpoint inhibitors (1:07:40) Case: A man in his early 70s with metastatic NSCLC develops a severe carboplatin-related allergy during treatment with carboplatin/nab paclitaxel/pembrolizumab (1:09:41) Benefits of early palliative care in the management of metastatic NSCLC (1:15:22) CME information and select publications
A case-based discussion on the management of metastatic non-small cell lung cancer. Interview with Leora Horn, MD, MSc and Yanjun Ma, MD conducted by Neil Love, MD. Produced by Research To Practice.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.
Dr. West moderates a question & answer session with Drs. Leora Horn and Taofeek OwonikokGreg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. West moderates a question & answer session with Drs. Leora Horn and Taofeek OwonikokGreg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. West moderates a question & answer session with Drs. Leora Horn and Taofeek OwonikokGreg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biospies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biospies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biospies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with Joel W Neal, MD, PhD, Paul K Paik, MD, Leora Horn, MD, MSc and Edward B Garon, MD, MS conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.
Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Leora Horn, MD, MSc conducted by Neil Love, MD. Produced by Research To Practice.
© 2020-2025 Ivy Podcast Discovery LLC
